12:42 PM EST - MedReleaf Corp. : Is introducing a ground-breaking, patent-pending, new genetic test called ReleafDxTM. This novel test analyzes a patient's DNA and health conditions to provide physicians with answers to two key questions: 1) what dosage should be prescribed; and 2) what cannabis product will work best for each individual. MedReleaf Corp.
shares T.LEAF are trading up $0.05 at $15.72.
